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common in Southeast Asia and northern Australia. In Thailand,
20%of all community-acquired cases of septicaemia are caused by© 2016 The Authors. Published by El
This is an open access artiB. pseudomallei, with 40% mortality. A striking rise in cases of
melioidosis was observed after the December 2004 tsunami, and
the disease was also more common after ﬂoods in Malaysia in
2015 (http://www.promedmail.org/direct.php?id=3218685). An
augmentation of imported cases in Western countries may be
strongly correlated with increased international travel (http://
mkt.unwto.org/barometer) [1]. Early diagnosis of melioidosis is
important considering the high mortality observed without
adequate antibiotic therapy [2]. Because empirical antibiotic
regimens for community-acquired pneumonia in nonendemic
countries may not provide adequate treatment for melioidosis
[3,4], effective tools are needed to rapidly diagnose melioidosis.Patients and MethodsMelioidosis was diagnosed in three French travellers in
December 2013 as well as in April and August 2015 at Hôpital
Avicenne, Bobigny, France. Patient characteristics are listed in
Table 1. Their management and outcome were strongly related
to the efﬁciency of the diagnosis.
The ﬁrst patient was admitted to the emergency department
with a 3-week history of community-acquired pneumonia with
treatment failure. Two days after admission, marked acute
respiratory distress and multiple organ failure occurred, leading
to the patient’s transfer to the intensive care unit for respira-
tory assistance and extracorporeal circulation. Concomitant
with the aggravation one blood culture drawn at admission was
positive Gram-negative bacilli on Gram stain. Subculture yiel-
ded Gram-negative, oxidase-positive bacilli which could not be
identiﬁed using a biochemical test strip (API20E; bioMérieux,
Marcy l’Étoile, France). Using molecular biology (partial
sequencing of the 16S rRNA gene), B. pseudomallei was identiﬁed
within 2 days. Susceptibility testing indicated a regular antimi-
crobial resistance pattern (Table 2).
Patient 2 was admitted shortly after his return from Borneo.
At this stage, he received no antibiotics. On day 3 of hospi-
talization, an aerobic blood culture drawn at admission yielded
Gram-negative bacilli. Rapid identiﬁcation using matrix-assisted
desorption ionization–time of ﬂight mass spectrometry
(MALDI-TOF MS; Microﬂex LT; Bruker Daltonics, Leipzig,
Germany) was performed directly on the pellet of the blood
culture [5]. Within less than 1 hour, the analysis yielded Bur-
kholderia thailandensis with a log score value of 1.83 (using the
standard Bruker v4.0 database). Querying the security-relevant
(SR) library, which includes bioterrorism agents (Bruker),
revealed B. pseudomallei, with a log score value of >2.0. The
identiﬁcation was conﬁrmed 5 days later by molecular biology
(targeting genes BpSCU2 and orf11 [6]). BiochemicalNew Microbe and New Infect 2016; 12: 31–34
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TABLE 1. Patient characteristics
Patient No.
Gender
(age, years) Clinical presentation (date) Visited country
Risk
factor Medical imaging Laboratory results biology Treatment (duration) Outcome
1 M (37) Fever and mild cough, rapid
evolution to acute respiratory
distress, multiple organ failure
(December 2013)
Thailand
(Kho Phangan)
None;
tattoo?
Chest x-ray revealed
cavity-like lesion in
upper lobe of right
lung compatible with
tuberculosis
 Leukocytes: 22.4 × 109 L
(81% neutrophils)
 HBV, HCV, HIV serologies:
negative
 Malaria test: negative
 PCT: 0.98 μg/L
 Amoxicillin (7 days)
 Amoxicillin-clavulanic
acid (7 extra days)
 Piperacillin-tazobactam +
amikacin
 Intravenous ceftazidime +
cotrimoxazole (14 days)
 Maintenance oral
cotrimoxazole (6 months)
After several weeks, acute renal failure
persisted along with reduced
respiratory capacity.
To date, no relapse observed.
2 M (36) Fever, chills, alteration of
general state (April 2015)
Malaysia
(Borneo)
None;
ﬂood?
Computed tomography
chest scan revealed
upper left lobe
condensation
 Leukocytes: 6.8 × 109 L
(82% neutrophils)
 HBV, HCV, HIV serologies:
negative
 Malaria test: negative
 PCT: 6.8 μg/L
 Intravenous ceftazidime and
oral cotrimoxazole (10 days)
 Maintenance oral
cotrimoxazole (3 months)
Favorable clinical outcome was observed
rapidly despite diagnosis of secondary
prostatic abscess. To date,
no relapse observed.
3 F (58) Fever, chills, acute respiratory
distress, diarrhoea, vomiting
(August 2015)
Cambodia Diabetes
mellitus
Chest x-ray revealed
alveolar condensation
lesions in lower lobe
of her left lung
 Leukocytes: 19.6 G/L
(88% neutrophils)
 HIV serology: negative
 PCT: 28.9 μg/L
 Intravenous ceftriaxone
for 24 hours; after bacterial
identiﬁcation, intravenous
ceftazidime and oral
cotrimoxazole (21 days)
 Maintenance oral
amoxicillin–clavulanic
acid (3 months)
Clinical course was rapidly favorable.
Sepsis and urinary tract infection
were observed 5 months after.
HBV, hepatitis B virus; HCV, hepatitis C virus; PCT, procalcitonin.
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TABLE 2. Antimicrobial susceptibility (disk diffusion test) of
three Burkholderia pseudomallei strains
Strain AMC CAZ IMP TS Gm DX CL
1 S S S S R S NT
2 S S S S S S NT
3 S S S S R S S
AMC, amoxicillin–clavulanic acid; CAZ, ceftazidime; CL, chloramphenicol; DX,
doxycycline; Gm, gentamicin; IMP, imipenem; NT, not tested; R, resistant; S,
sensitive; TS, trimethoprim–sulfamethoxazole (cotrimoxazole).
NMNI Walewski et al. Melioidosis diagnosis by MALDI-TOF MS 33characterization (API20NE; bioMérieux) yielded Chromobacte-
rium violaceum, a frequent misidentiﬁcation [7]. Antimicrobial
susceptibility testing by disk diffusion revealed susceptibility to
compounds used in conventional treatment but an abnormal
sensitivity to aminoglycosides (e.g. gentamicin) (Table 2).
Patient 3was originally a native ofCambodia; she has resided in
France for 30 years but frequently returns to her home country.
Culture of aerobic blood drawn at admission yielded Gram-
negative bacilli. As in patient 2, the bacilli were identiﬁed within
less than an hour with MALDI-TOF MS as B. pseudomallei, with a
log score value >2.0 using the SR library. Antimicrobial suscep-
tibility was identical to that of the isolate of patient 1. A relapse
was observed 5 months later despite good therapy compliance.DiscussionUnderlying predisposing conditions such as diabetes mellitus
have been widely described (e.g. patient 3). Patients 1 and 2 had
no evident risk factors, but in patient 1, skin lesions related to a
tattoo may have constituted a source of exposure [2]. There
was a difference in the clinical presentation of the cases: patient
1 had a history of more than 2 weeks of inappropriate therapy,
which may have led to body-wide dissemination of the path-
ogen, possibly explaining the severity of the clinical evolution.
Culture is the reference standard for the microbiologic diag-
nosis of melioidosis. B. pseudomallei grows easily on standard
mediawithin 24 to 48 hours. Culture readingmay be facilitated by
using selective media, e.g. Ashdown medium, which is not widely
used in nonendemic countries. Rapid diagnostic tools are also
available in endemic countries, based on immunoﬂuorescence,
monoclonal antibodies or latex agglutination. In nonendemic
countries, difﬁculties in identiﬁcation stem from the lack of fa-
miliarity with the cultural characteristics and the nonuse of
effective and speciﬁc diagnostic facilities. Above all,
B. pseudomallei is usually misidentiﬁed as a culture contaminant
when standard identiﬁcation techniques are used (e.g. API20NE,
automated Vitek) [7]. Moreover, many Malaysian strains show
quite unusual biochemical characteristics and susceptibility to
gentamicin, which may be misleading [7].© 2016 The Authors. Published by Elsevier Ltd on behal
This is an open access articIn the cases reported here, the microbiologic diagnosis was
made in two ways. In the ﬁrst case, identiﬁcation of
B. pseudomallei by phenotypic and molecular approaches took at
least 4 days after the blood culture turned positive. In the two
other cases, identiﬁcation with MALDI-TOF MS gave a result
the same day the blood culture turned positive.
MALDI-TOF MS has been shown to be an accurate and rapid
procedure for identiﬁcation of B. pseudomallei if the appropriate
database is used. Because this pathogen is not represented in
the Main Spectra Bruker Biotyper database, the response ob-
tained with this database is B. thailandensis, with average log
score values reﬂecting the closeness of the two species and
shared peaks in their mass spectra [8]. Identiﬁcation of Bur-
kholderia species at the genus level using the standard Bruker
database should alert the microbiologist and trigger further
speciﬁc characterization. Speed in the detection of
B. pseudomallei in blood cultures allowed us to set up effective
antibiotic therapy and protective measures without delay for
laboratory workers. Indeed, precautions must be taken in
manipulating this pathogen, as it is considered to be a bioter-
rorism agent. Cultures must be handled under biosafety level 3
laboratory conditions. Incidents of exposure of laboratory
workers have been reported [1].
International travel increases the potential spread of infectious
diseases, and the number of travellers to endemic areas will
inexorably expand. Nonendemic countries will have to face
increasing rates of imported cases that must be diagnosed rapidly
using efﬁcient procedures. Difﬁculties in laboratory diagnosis of
melioidosis may delay adequate treatment and affect disease
outcome. MALDI-TOF MS can be applied successfully to the
identiﬁcation of B. pseudomallei if a suitable database is used.AcknowledgementsThe authors thank E. Valade and the Institut de Recherche
Biomédicale des Armées for the molecular analysis. We also
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